Abstract Details

Title Validation of the revised classification of cognitive and behavioral impairment in ALS

Topic Neuromuscular and Clinical Neurophysiology (EMG)

Presentation(s) P1 - Poster Session 1 (5:30 PM-6:30 PM)

Poster/Presentation
Number 12-008

Objective To compare the extent and the characterization of cognitive impairment in ALS patients using both previous and novel diagnostic criteria.

Background

In 2017, criteria for the diagnosis of cognitive impairment in ALS (ALSFTD-1) have been partially modified (ASLFTD-2) with the inclusion of a novel category (ALS with cognitive and behavioural impairment, ALScbi) and with changes in the defintion of the remaining (ALS with cognitive impairment, ALSci, ALS with behavioural impairment, ALS bi, ALS with fronto-temporal dementia, ALS-FTD).

Design/Methods Two cohorts of patients who had experienced ALS diagnosis in the 2014-2017 period were enrolled: a population-based cohort including patients from the Piedmont and Aosta Valley register (PARALS)(n=321) and a referral cohort of patients residents out of the PARALS regions (n=205). Cognitive functions were assessed by two neupsychologist in blind.

Results According to ALSFTD-2, 84 (15.9%) of overall patients changed their cognitive status with respect to ALSFTD-1 classification. In particular, 34 patients previously classified as cognitive normal were reclassified either as ALSci (25) or as ASLbi (9). Two patients moved from ASLci to ALS-FTD. Finally, 6 ALSbi and 42 ALSci patients were reclassified as ASLcbi. ALScbi patients showed a survival intermediate between those of ALS-FTD and ALSci (2.6 years, 95% CI 2.1-3.3).

Conclusions

The novel ALSFTD-2 criteria showed a higher capability of detecting cognitive impairment and a better prognostic value then previous ones.

Authors/Disclosures
Rosario Vasta, MD (University of Turin, Department of Neurosciences) PRESENTER	Dr. Vasta has nothing to disclose.
	No disclosure on file
	No disclosure on file
Andrea Calvo, MD, PhD, FAAN (Dept. of Neuroscience, University of Turin)	Dr. Calvo has nothing to disclose.
Cristina Moglia (University of Torino)	Cristina Moglia has nothing to disclose.
Antonio Canosa	Antonio Canosa has nothing to disclose.
Umberto Manera, MD (Department of Neuroscience "Rita Levi Montalcini" - University of Torino)	Dr. Manera has nothing to disclose.
	No disclosure on file
Alessandro Bombaci, MD (Rita Levi Montalcini Department of Neuroscience, University of Turin)	Dr. Bombaci has nothing to disclose.
	No disclosure on file
Gabriele Mora, MD	Dr. Mora has nothing to disclose.
Barbara Iazzolino	Barbara Iazzolino has nothing to disclose.
Adriano Chio, MD, FAAN (Dept. of Neuroscience, University of Turin)	Dr. Chio has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cytokinetics. Dr. Chio has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Mitsubishi. Dr. Chio has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Chio has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Corcept.

��ɫ��

��ɫ��